Syndax Pharmaceuticals (SNDX) EBITDA Margin (2015 - 2026)
Syndax Pharmaceuticals (SNDX) recorded quarterly EBITDA Margin of 52.73% in Q1 2026, up 42.06% quarter-over-quarter from 91.01% in Q4 2025, and up 36518.0% on a YoY basis from N/an in Q1 2025.
Syndax Pharmaceuticals (SNDX) EBITDA Margin (2015 - 2026) Analysis & Trends
Syndax Pharmaceuticals' EBITDA Margin history runs 10 years deep, the most recent figure standing at 52.73% for Q1 2026.
- In Q1 2026, EBITDA Margin rose 36518.0% year-over-year to 52.73%; the TTM figure through Mar 2026 stood at 102.81% (up 65467.0% YoY), while the FY2025 annual figure was 158.45%, up 127598.0% from the prior year.
- EBITDA Margin was 52.73% for Q1 2026 at Syndax Pharmaceuticals, up from 91.01% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 52.73% in Q1 2026 to a low of 1946.4% in Q2 2024.
- Historically, EBITDA Margin has averaged 591.78% across 3 years, with a median of 300.31% in 2025.
- The sharpest annual moves came in 2025 and 2026: EBITDA Margin surged 176369 bps in 2025, then jumped 36518 bps in 2026.
- A 3-year view of EBITDA Margin shows it stood at 1254.75% in 2024, then jumped by 93 bps to 91.01% in 2025, then soared by 42 bps to 52.73% in 2026.
- The last three EBITDA Margin figures came in at 52.73% (Q1 2026), 91.01% (Q4 2025), and 125.19% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Syndax Pharmaceuticals | 1.69 Bn | 1.34 Bn | 53.02 Mn | -52.73% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -52.73% |
| Dec 31, 2025 | -91.01% |
| Sep 30, 2025 | -125.19% |
| Jun 30, 2025 | -182.71% |
| Mar 31, 2025 | -417.91% |
| Dec 31, 2024 | -1,254.75% |
| Sep 30, 2024 | -663.50% |
| Jun 30, 2024 | -1,946.40% |
| Dec 31, 2021 | 75.65% |
| Sep 30, 2021 | -166.83% |
| Jun 30, 2021 | -6,042.74% |
| Mar 31, 2021 | -7,311.35% |
| Dec 31, 2020 | -5,226.32% |
| Sep 30, 2020 | -5,409.23% |
| Jun 30, 2020 | -4,483.64% |
| Mar 31, 2020 | -4,007.39% |
| Dec 31, 2019 | -3,738.16% |
| Sep 30, 2019 | -3,393.67% |
| Jun 30, 2019 | -3,922.43% |
| Mar 31, 2019 | -3,764.91% |